Clinical Overview
Tacrolimus (0.03%, 0.1% ointment) is a topical calcineurin inhibitor (TCI) and non-steroidal immunosuppressant on the WHO Model List of Essential Medicines. It binds to intracellular immunophilin FKBP-12, forming a complex that inhibits calcineurin phosphatase, preventing dephosphorylation of NF-AT and blocking transcription of pro-inflammatory cytokines (IL-2, IL-3, IL-4, IFN-gamma) in T-lymphocytes. Unlike steroids, it does not cause skin atrophy, telangiectasia, or collagen breakdown. Indicated for moderate-to-severe atopic dermatitis (eczema) in patients not adequately responsive to or intolerant of conventional topical therapies, especially on the face, neck, and flexures.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Apply a thin film to affected skin twice daily. Gently rub in. Avoid bathing or swimming immediately after application. Transient burning/stinging sensation during the first few days of therapy is expected and resolves with continued use.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Application site burning, stinging, erythema, pruritus, alcohol intolerance (facial flushing with alcohol). Rare/Severe: Boxed warning: Malignancy risk (rare reports of lymphoma and skin malignancies); secondary viral skin infections (eczema herpeticum, molluscum).
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warning: Avoid continuous long-term use; apply as short-term or intermittent therapy. Do not use under occlusive dressings. Avoid UV light, sun exposure, and tanning beds; use photoprotection. Contraindicated in Netherton's syndrome due to increased systemic absorption.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered dermatologist or qualified medical practitioner before initiating, altering, or substituting any topical or systemic dermatological treatment.